Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eisai
Woman and Man
Between 2 years and 25 years
Eisai Medical Research Inc.
Update Il y a 4 ans
Étude E7080-G000-207 : étude non-randomisée de phase 1 / 2 évaluant la sécurité, la tolérance et l’efficacité du lenvatinib chez des enfants et des adolescents ayant une tumeur solide maligne réfractaire ou récidivante et des jeunes adultes ayant un ostéosarcome. [essai clos aux inclusions]
Le cancer est la première cause de mortalité par maladie chez les enfants et les adolescents. Le cancer de la thyroïde pédiatrique représente 10% des tumeurs malignes et 35% des carcinomes infantiles....
Country
France
organs
Tumeurs solides
,
Os
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 4 ans
Lemborexant for the treatment of insomnia disorder in older individuals LEMBOREXANTA PARA EL TRATAMIENTO DE INSOMNIO EN ADULTOS MAYORES
Demonstrate using polysomnography (PSG) that 10 mg lemborexant (LEM10) is superior to zolpidem tartrate ER 6.25 mg (Ambien CR; ZOL) on objective sleep maintenance as assessed by wake after sleep onset...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 4 ans
Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease
The primary objective of this study is to compare 23 mg donepezil SR with 10 mg donepezil IR in the treatment of patients with moderate to severe Alzheimer’s disease.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatments
Compare the overall survival (OS) of patients receiving E7080 + BSC with those receiving placebo + best supportive care (BSC)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 4 ans
An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures
To assess the long-term safety of zonisamide used as an adjunctive treatment in paediatric subjects treated with one or two other anti-epileptic drugs (AEDs).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A Phase 2 trial to determine if there is a lower starting dose of lenvatinib (20mg or 14mg daily) that will cause fewer side effects and work as well as a 24mg starting dose in treating adults with thyroid cancer, who are not responding to treatment, or whose cancer has reappeared following an initial recovery
To determine whether a starting dose of lenvatinib 20 mg or 14 mg once daily (QD) will provide comparable efficacy (based on ORR6M) with an improved safety profile compared to 24 mg QD (based on treat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS AND “ON” PERIOD DYSKINESIAS
1. To evaluate the long-term safety and tolerability of E2007, in patients with Parkinson’s disease with “wearing-off” motor fluctuations and on-period dyskinesias
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Eisai Medical Research Inc.
Update Il y a 4 ans
E7389-G000-398 : Essai évaluant l’usage de l’éribuline chez des patientes ayant un cancer du sein avancé réfractaire. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’innocuité du mésylate d’éribuline chez des patientes ayant un cancer du sein avancé réfractaire. Les patientes recevront une injection de mésylate d’éribuline ...
Country
France
organs
Sein
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease
To assess the safety and tolerability of E5555 in patients with coronary artery disease.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia
To compare the overall survival in patients 65 years and older who have newly diagnosed de novo or secondary Acute Myloid Leukemia and either poor or intermediate risk cytogenetics who are randomly as...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
Next